Harpreet Singh, Immatics CEO
June 2, 2022 09:02 AM EDT
Deals
Cell/Gene Tx

Im­mat­ics imag­ines broad­er CAR-T pipeline with an­oth­er Bris­tol My­ers pact and ad­di­tion to 2019 TCR deal

Kyle LaHucik

Senior Reporter

Im­mat­ics is hit­ting the gas ped­al on an­oth­er Bris­tol My­ers Squibb deal as the biotech-Big Phar­ma pair al­so lev­el up their 2019 pact, orig­i­nal­ly inked …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

Will CRISPR mat­ter?

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times